Testing ZP9830 for safety and effects in adults with plaque psoriasis
Tests ZP9830 against placebo for 8 weeks in adults with plaque psoriasis.
Plain-language title generated from the registry record
Registry title: A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period
Key facts
- Where
- Leiden, NetherlandsSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07733089, who can take part
Where in Netherlands
- Centre for Human Drug ResearchLeiden, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zealand Pharma
- Trial code
- NCT07733089EU 2026-525220-15-00
- Record updated
- 29 July 2026
- Original description
The purpose of this trial is to investigate the effects of repeated administration of ZP9830 for 8 weeks in participants with plaque psoriasis. Here, the primary aim is to evaluate safety and tolerability of ZP9830, the secondary aims are to test clinical efficacy and pharmacokinetics, and lastly the exploratory aim is to test the pharmacodynamic effects of ZP9830 treatment.Read full original descriptionShow less
An Interventional, Randomized, Double-blind, Placebo-controlled, Multiple Dose Trial Evaluating Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Clinical Efficacy of ZP9830 Administered for 8 Weeks in Participants With Plaque Psoriasis
The purpose of this trial is to investigate the effects of repeated administration of ZP9830 for 8 weeks in participants with plaque psoriasis. Here, the primary aim is to evaluate safety and tolerability of ZP9830, the secondary aims are to test clinical efficacy and pharmacokinetics, and lastly the exploratory aim is to test the pharmacodynamic effects of ZP9830 treatment.
Inclusion: Participants with a confirmed diagnosis of psoriasis (stable plaque psoriasis ≥ 2 months); Participants who have ≥ 2 vulgar psoriatic plaques; BMI within the range 18.0-35.0 kg/m2 (inclusive); Further inclusion criteria apply.
Exclusion: Use of any concurrent systemic medications that could affect psoriasis or psoriasis evaluation, including corticosteroids, retinoids, cyclosporine, methotrexate, PDE4s (phosphodiesterase 4), or biologic agents within 30 days prior to IMP administration or planned to use during the course of the trial; Use of concurrent topical medications containing corticosteroids, retinoids, calcitriol or other topical medication relevant to psoriasis treatment (must be discontinued at least 2 weeks prior to baseline); Use of UVA, PUVA, or UVB therapy and tanning beds within 4 weeks of baseline or during trial participation; Use of any biologic or advance systemic therapies for any autoimmune disease within the last 12 months; Current drug-induced or aggravated psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta-blockers, calcium-channel blockers, or lithium carbonate); Any clinically significant abnormalities, as judged by the investigator, in laboratory test results (including hematology, biochemistry, and urinalysis); Erythrodermic, predominantly guttate, exclusively palmar/plantar, or generalized pustular psoriasis; Any clinically significant abnormal findings during the standardized neurological examination conducted at screening; Further exclusion criteria apply.